Confocal image showing the cytoskeleton of peritubular myoid cells differentiated in vitro from human induced pluripotent stem cells; smooth muscle actin 2 is in red, F-actin in blue, tubulin beta III in green, and nuclei in cyan.

Peritubular myoid cells are key ingredients for sperm production. Differentiating them in the lab helps recreate the testicular environment for studying infertility.

Credit: Flannigan lab

Unlocking fertility’s secret recipe using lab-created cells

In a step towards understanding spermatogenesis and infertility, researchers created testicular cells that are key to sperm transport from human stem cells.
Alejandra Manjarrez headshot
| 3 min read
Register for free to listen to this article
Listen with Speechify
0:00
3:00

When it comes to male fertility, the spotlight often falls on sperm. Yet germ cell production and transport require other cell types in the testicles to run smoothly. Peritubular myoid (PTM) cells, which give structure to the seminiferous tubes and contract to help spermatozoa move through these tubules, are one of these key ingredients. 

Ryan Flannigan, a reproductive surgeon and scientist at the University of British Columbia, wanted to better understand the mechanisms involved in impaired sperm production. To achieve this, Flannigan explained, “We use human tissue samples from very generous patients that allow us to use some of their tissue for research, but for all of the experiments that we’re looking to do and technologies we’re looking to develop, it’s certainly a limited resource.”

Scientists can address these constraints by generating populations of different testicular cell types using human-derived cells. While many lab-created testicular cells are available, PTM cells were a missing piece. Recently, Flannigan and his colleagues differentiated PTM cells from human induced pluripotent stem cells (hiPSC) for the first time and reported the feat in Advanced Biology (1).

A bioprinter at work in Flannigan’s laboratory: a series of nozzles ready to print 3D structures in a Petri dish.
3D bioprinters supplied with different testicular cell types facilitate engineering the testicular niche.
Credit: Flannigan lab

“Fundamentally speaking, it is interesting to study peritubular myoid cell development and differentiation,” said reproductive biologist Ina Dobrinski at the University of Calgary who did not participate in this study. And to that end, she agreed with Flannigan; the human-derived material is exceedingly limited, and that makes his achievement significant. 

During development, PTM cells derive from the same progenitor cells as Leydig cells, which are responsible for producing testosterone. Flannigan’s team modified a protocol for differentiating Leydig cells from hiPSC (2). Next, they looked at the genes expressed by the resulting cells and compared them to those of PTM cells obtained from a patient’s testicular biopsy to confirm that they had derived cells with PTM-like transcriptomes. 

“What we're really focusing on now is being able to use these cell populations as the substrate for optimizing three-dimensional architecture within the testicle,” Flannigan said. He added that these in vitro generated cells could help researchers better understand human spermatogenesis or even lead to a regenerative platform for fertility treatments.

Currently, Flannigan and his colleagues employ 3D bioprinting techniques to pursue these goals. They use microfluidic 3D bioprinters to deposit specific human testicular cell types within bioink, a liquid composed of various proteins including collagen. “Then, we can design where we want to place those cells relative to the other cells,” Flannigan explained. His team has previously bioprinted testicular tubules using human adult testicular cells from a patient and shown that the structures maintained cell viability after printing (3). “Having that ability to have those [in vitro generated cell] populations allows us to move that technology forward,” he said.

While Dobrinski said that we might still be far from building a testis niche with direct clinical applications such as fertility preservation, cultivating PTM cells in the lab constitutes a significant piece of the puzzle. 

References

  1. Robinson, M. et al. Differentiation of Peritubular Myoid-Like Cells from Human Induced Pluripotent Stem Cells. Adv Biol (Weinh)  7, e2200322 (2023).
  2. Chen, X. et al. Differentiation of human induced pluripotent stem cells into Leydig-like cells with molecular compounds. Cell Death Dis  4, 220 (2019). 
  3. Robinson, M. et al. Using clinically derived human tissue to 3-dimensionally bioprint personalized testicular tubules for in vitro culturing: first report. F&S Sci  3, 130-139 (2022).

About the Author

  • Alejandra Manjarrez headshot
    Alejandra Manjarrez was an assistant editor at Drug Discovery News in 2023. She is now a freelancer.  She has written for The Scientist, Science, Knowable Magazine, The Atlantic, and others. 

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue